Schroder Investment Management Group Increases Position in Edwards Lifesciences Corporation $EW

Schroder Investment Management Group lifted its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 1,657.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,133,475 shares of the medical research company’s stock after acquiring an additional 1,068,979 shares during the quarter. Schroder Investment Management Group owned 0.20% of Edwards Lifesciences worth $88,150,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. True Wealth Design LLC grew its stake in Edwards Lifesciences by 251.5% in the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 259 shares during the period. Hantz Financial Services Inc. raised its stake in shares of Edwards Lifesciences by 76.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock worth $29,000 after purchasing an additional 164 shares during the period. Rakuten Securities Inc. raised its stake in shares of Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after purchasing an additional 302 shares during the period. Steigerwald Gordon & Koch Inc. purchased a new position in shares of Edwards Lifesciences in the 3rd quarter worth about $30,000. Finally, Strengthening Families & Communities LLC purchased a new position in shares of Edwards Lifesciences in the 3rd quarter worth about $34,000. 79.46% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, VP Donald E. Bobo, Jr. sold 11,340 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $85.93, for a total transaction of $974,446.20. Following the completion of the transaction, the vice president directly owned 21,266 shares in the company, valued at $1,827,387.38. The trade was a 34.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $85.70, for a total value of $87,328.30. Following the completion of the transaction, the vice president owned 22,002 shares in the company, valued at $1,885,571.40. This represents a 4.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 71,444 shares of company stock worth $6,035,269 in the last quarter. 0.34% of the stock is currently owned by company insiders.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $84.21 on Tuesday. The company has a 50 day moving average of $82.51 and a 200 day moving average of $81.49. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06. The stock has a market cap of $48.91 billion, a P/E ratio of 46.02, a P/E/G ratio of 2.13 and a beta of 0.93. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.89.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The firm had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.54 billion. During the same quarter in the prior year, the company earned $0.59 earnings per share. The business’s revenue for the quarter was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, sell-side analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

EW has been the subject of a number of research analyst reports. UBS Group restated a “neutral” rating and set a $94.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, February 4th. Royal Bank Of Canada boosted their target price on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a research note on Friday, December 5th. Wells Fargo & Company increased their target price on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Canaccord Genuity Group set a $87.00 price target on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research note on Wednesday, December 17th. Finally, Stifel Nicolaus set a $110.00 price target on shares of Edwards Lifesciences and gave the stock a “buy” rating in a report on Tuesday, January 20th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and an average target price of $96.14.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.